Kidney Cancer Drugs Global Market Report 2021: COVID-19 Impact And Recovery To 2030

The Business Research Company’s Kidney Cancer Drugs Global Market Report 2021: COVID-19 Impact And Recovery

LONDON, GREATER LONDON, UK, August 6, 2021 /EINPresswire.com/ -- According to the new market research report ‘Kidney Cancer Drugs Global Market Report 2021: COVID-19 Impact And Recovery To 2030’ published by The Business Research Company, the kidney cancer drugs market is expected to decline from $3.3 billion in 2020 to $3.29 billion in 2021 at a compound annual growth rate (CAGR) of -0.3%. The slow decline is mainly due to the outbreak of COVID-19 that has led to the deferment of immunocompromised treatments. The kidney cancer drugs market is expected to reach $3.6 billion in 2025 at a CAGR of 2.3%. The rise in the incidence of renal cancer acts as one of the major drivers of the kidney cancer drugs market.

Request For A Sample For The Global Kidney Cancer Drugs Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2591&type=smp

The kidney cancer drugs market consists of sales of kidney cancer drugs. It includes immunotherapy, chemotherapy, and targeted therapy.

Trends In The Global Kidney Cancer Drugs Market
The use of combination therapy is trending in the kidney (renal) cancer drugs market. Combination therapy combines the effects of various drugs thereby reducing the likelihood of cancer-resistant cells from developing. The improved understanding of renal cancer causes and effects has led to the discovery of combination therapy. Under this treatment, the drugs from vascular endothelial growth factor (VEGF), which stimulate the protein in the blood are combined with inhibitors of the mammalian target of rapamycin (mTOR), which helps promote cellular biogenesis. According to a study conducted by the National cancer institute (NIH) in 2019, the combination treatment leads to better outcomes in patients suffering from advanced kidney cancer. In April 2019, Merck attained food and drug administration (FDA) approval to combine their drug Pembrolizumab, which enhances the patients’ immune system along with Pfizer’s drug Axitinib, which prevents the spread of renal cancer, this combination of drugs can help increase the pace of the patients’ recovery in advanced kidney cancer.

Global Kidney Cancer Drugs Market Segments:
The global kidney cancer drugs market is further segmented based on type, product, end users and geography.

By Type: Renal Cell Carcinoma (RCC), Transitional Cell Carcinoma (TCC), or Urothelial cell carcinoma (UCC)

By Product: Nexavar (Sorafenib), Sutent (Sunitinib), Afinitor (Everolimus), Votrient (Pazopanib), Avastin (Bevacizumab), Inlyta (Axitinib), Torisel (Temsirolimus), Proleukin (Aldesleukin), Others

By End Users: Hospitals, Clinics, Research Center, Others

By Geography: The global renal cancer drugs market is segmented into North America, South America, Asia-Pacific, Eastern Europe, Western Europe, Middle East and Africa.

Read More On The Report For The Global Kidney Cancer Drugs Market At:
https://www.thebusinessresearchcompany.com/report/kidney-cancer-drugs-global-market-report

Kidney Cancer Drugs Global Market Report 2021 is one of a series of new reports from The Business Research Company that provides kidney cancer drugs global market overviews, analyzes and forecasts global market size and growth for the global kidney cancer drugs market, kidney cancer drugs global market share, kidney cancer drugs global market players, kidney cancer drugs global market segments and geographies, kidney cancer drugs market’s leading competitors’ revenues, profiles and market shares. The kidney cancer drugs market report identifies top countries and segments for opportunities and strategies based on market trends and leading competitors’ approaches.

Read Kidney Cancer Drugs Global Market Report 2021 from The Business Research Company for information on the following:

Data Segmentations: Market Size, Global, By Region And By Country; Historic And Forecast Size, And Growth Rates For The World, 7 Regions And 12 Countries

Kidney Cancer Drugs Market Organizations Covered: Bayer AG, Pfizer Inc., Novartis International AG, Exelixis, Inc., and F. Hoffmann-La Roche AG.

Regions: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.

Countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Interested to know more about The Business Research Company?
The Business Research Company has published over 1000 industry reports, covering over 2500 market segments and 60 geographies. The reports draw on 150,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. The reports are updated with a detailed analysis of the impact of COVID-19 on various markets. Here is a list of reports from The Business Research Company similar to the Kidney Cancer Drugs Global Market Report 2021:

Cervical Cancer Diagnostics Global Market Report 2021: COVID-19 Growth And Change To 2030
https://www.thebusinessresearchcompany.com/report/cervical-cancer-diagnostics-market-report

Cancer Diagnostics Global Market Report 2021: COVID-19 Growth And Change To 2030
https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

Oncology Drugs Global Market Report 2021: COVID-19 Impact And Recovery To 2030
https://www.thebusinessresearchcompany.com/report/oncology-drugs-global-market-report

Call us now for personal assistance with your purchase:
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

The Business Research Company
Email: info@tbrc.info
Follow us on LinkedIn: https://bit.ly/3b7850r
Follow us on Twitter: https://bit.ly/3b1rmjS
Check out our Blog: http://blog.tbrc.info/

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
info@tbrc.info
Visit us on social media:
Facebook
Twitter
LinkedIn